Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, Ambrose CS, Cook B, Martin N, Spahn J, Llanos JP. Corren J, et al. Eur Respir J. 2023 Mar 30;61(3):2202202. doi: 10.1183/13993003.02202-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36997233 Free article. No abstract available.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: corren j. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Corren J, Menzies-Gow A, Bimmel J, McGuinness A, Almqvist G, Bowen K, Griffiths JM, Ponnarambil S, Bourdin A, Israel E, Colice G, Brightling CE, Wechsler ME; PATHWAY and NAVIGATOR study investigators. Corren J, et al. Immunotherapy. 2023 Nov;15(16):1327-1340. doi: 10.2217/imt-2023-0109. Epub 2023 Sep 29. Immunotherapy. 2023. PMID: 37772607 Review.
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Among authors: corren j. Ann Allergy Asthma Immunol. 2024 Apr 30:S1081-1206(24)00280-1. doi: 10.1016/j.anai.2024.04.031. Online ahead of print. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article.
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Pavord ID, et al. Among authors: corren j. J Allergy Clin Immunol Pract. 2024 Mar 29:S2213-2198(24)00306-4. doi: 10.1016/j.jaip.2024.03.031. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38555079 Free article.
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, Berman G, Brusselle G, Zitnik R, Natalie CR, Sun L, Siu K, Wu WS, Lio P, Armstrong AW. Corren J, et al. J Allergy Clin Immunol Pract. 2024 May;12(5):1215-1224.e3. doi: 10.1016/j.jaip.2024.02.007. Epub 2024 Feb 14. J Allergy Clin Immunol Pract. 2024. PMID: 38360213 Free article. Clinical Trial.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: corren j. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
174 results